Dermata holders report 4.99% beneficial stake
Dermata Therapeutics, Inc. reporting persons disclosed beneficial ownership of 211,246 shares of common stock, representing 4.99% of the class.
Rhea-AI Filing Summary
Dermata Therapeutics, Inc. reporting persons disclosed beneficial ownership of 211,246 shares of common stock, representing 4.99% of the class. The position reflects shares issuable upon exercise of four warrants and is calculated using March 25, 2026 outstanding share data.
The filing states a blocker provision limits exercise of part of one warrant (Intracoastal Warrant 4), excluding 111,453 shares from the ownership total; without the blocker the reporting persons may be deemed to beneficially own 322,699 shares.
Positive
- None.
Negative
- None.
Insights
Warrant-driven holding equals a 4.99% passive stake under a blocker clause.
Dermata reporting persons report beneficial ownership of 211,246 shares, computed using March 25, 2026 outstanding shares of 4,022,143. The position is entirely attributable to four warrants held by Intracoastal and related persons.
The filing highlights a blocker provision in Intracoastal Warrant 4 that excludes 111,453 exercisable shares; without that provision the filing states a higher beneficial ownership figure of 322,699 shares. Subsequent filings would show any exercise or lifting of the blocker.
Disclosure is routine passive ownership reporting under Schedule 13G/A.
The filing identifies the reporting persons (Mitchell P. Kopin, Daniel B. Asher, Intracoastal Capital LLC) and states shared voting and dispositive power over 211,246 shares. It frames the holding as ≤5% and cites the issuer-supplied outstanding share count used for the calculation.
Material dependency is the blocker clause language; governance or control implications hinge on whether warrants are exercised or transferred. Future filings will disclose any exercises or changes in percent ownership.
Key Figures
Key Terms
blocker provision regulatory
beneficial ownership financial
warrant financial
FAQ
What stake does DRMA reporting persons hold?
How is the 4.99% ownership in DRMA calculated?
What is the blocker provision mentioned in the DRMA filing?
Who are the reporting persons in the DRMA 13G/A?
Would the reported ownership change if warrants are exercised?
AI-generated analysis. How Rhea-AI works. Not financial advice.